Evidence map›Paper›PMID 39198902›Full record

ArticleDiagnostic pathology2024

Exploring LGR5 as a prognostic marker of extrahepatic cholangiocarcinoma: insights from expression analysis and clinical correlations.

Hisashi Tamada, Takeshi Uehara, Takahiro Yoshizawa, Mai Iwaya, Shiho Asaka, Tomoyuki Nakajima, Masato Kamakura, Hiroyoshi Ota

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hisashi TamadaDepartment of Pathology, Nagano Red Cross Hospital, Nagano, Japan.
Takeshi UeharaDepartment of Laboratory Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. tuehara@shinshu-u.ac.jp.
Takahiro YoshizawaDepartment of Gastroenterological, Pediatric and Transplant Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Mai IwayaDepartment of Laboratory Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Shiho AsakaDepartment of Laboratory Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Tomoyuki NakajimaDepartment of Laboratory Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Masato KamakuraDepartment of Gastroenterology, Nagano Red Cross Hospital, Nagano, Japan.
Hiroyoshi OtaDepartment of Laboratory Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Funding

Hokuto Foundation for Bioscience noneJapan Society for the Promotion of Science Grant-in-Aid for Scientific Research (KAKENHI) 20K07405Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (KAKENHI) 22K07414
6 · The paper itself

Abstract

backgroundLeucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) is a cancer stem cell (CSC) marker of colorectal cancer and may be a CSC marker of other cancer types. Few studies have been conducted on LGR5 expression in extrahepatic cholangiocarcinoma (ECC).

methodsWe analyzed LGR5 expression using RNAscope, a highly sensitive RNA in situ hybridization technique. Fifty-three ECCs were selected from the medical archives at Shinshu University Hospital and analyzed using a tissue microarray. LGR5 expression levels were divided into expression and no expression groups. LGR5 expression and clinicopathological characteristics were analyzed.

resultsAmong 25 cases, no LGR5-positive dots were identified. Among 28 cases, some LGR5-positive dots were observed in carcinoma cells, together with a wide range of LGR5-positive cells. LGR5 expression was conspicuous in glandular duct formations. Well- to moderately differentiated types showed significantly higher LGR5 expression than the poorly differentiated type (p = 0.0268). LGR5 expression was associated with good overall survival (p = 0.0219) and good disease-free survival (DFS) (p = 0.0228). High LGR5 expression was associated with well- to moderately-differentiated types, indicating a favorable prognosis. In terms of DFS, multivariate analysis showed that high LGR5 expression was an independent favorable prognostic factor (p = 0.0397).

conclusionsThese findings suggest that LGR5 is a promising, novel prognostic marker.

Indexed as

Bile Duct NeoplasmsBiomarkers, TumorCholangiocarcinomaReceptors, G-Protein-CoupledAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansMaleMiddle AgedPrognosisBiomarkers, TumorLGR5 protein, humanReceptors, G-Protein-CoupledExtrahepatic cholangiocarcinomaLeucine-rich repeat-containing G protein-coupled receptor 5RNA in situ hybridization

Identifiers

PMID39198902
PMCPMC11350935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.